Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Topol

Showing results (81-90 of 605) with videos related to

Pageof 61
Sort By:
Arthritis Research & Therapy|April 30, 2003
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitorsDebabrata Mukherjee, Eric J Topol
The American Journal of Cardiology|March 5, 2004
Lack of adverse clopidogrel-atorvastatin clinical interactionJacqueline Saw, Eric J Topol
Lancet (London, England)|June 1, 2021
Artificial intelligence, bias, and patients' perspectivesZiad Obermeyer, Eric J Topol
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fightDeepak L Bhatt, Eric J Topol
Nature Clinical Practice. Cardiovascular Medicine|September 19, 2007
Is there a genetic basis for acute coronary syndrome?Bradley A Patay, Eric J Topol
Annals of Internal Medicine|June 4, 2020
Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative ReviewDaniel P Oran, Eric J Topol
The New England Journal of Medicine|October 6, 2016
State of TelehealthE Ray Dorsey, Eric J Topol
Journal of Biopharmaceutical Statistics|March 24, 2010
Genotype-based risk and pharmacogenetic sampling in clinical trialsNicholas J Schork, Eric J Topol
Nature Genetics|September 29, 2006
The genetics of healthJoseph H Nadeau, Eric J Topol
Nature Genetics|March 30, 2007
The resequencing imperativeEric J Topol, Kelly A Frazer
Pageof 61

Showing results (81-90 of 605) with videos related to

Sort By:
Pageof 61
Arthritis Research & Therapy|April 30, 2003
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitorsDebabrata Mukherjee, Eric J Topol
The American Journal of Cardiology|March 5, 2004
Lack of adverse clopidogrel-atorvastatin clinical interactionJacqueline Saw, Eric J Topol
Lancet (London, England)|June 1, 2021
Artificial intelligence, bias, and patients' perspectivesZiad Obermeyer, Eric J Topol
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fightDeepak L Bhatt, Eric J Topol
Nature Clinical Practice. Cardiovascular Medicine|September 19, 2007
Is there a genetic basis for acute coronary syndrome?Bradley A Patay, Eric J Topol
Annals of Internal Medicine|June 4, 2020
Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative ReviewDaniel P Oran, Eric J Topol
The New England Journal of Medicine|October 6, 2016
State of TelehealthE Ray Dorsey, Eric J Topol
Journal of Biopharmaceutical Statistics|March 24, 2010
Genotype-based risk and pharmacogenetic sampling in clinical trialsNicholas J Schork, Eric J Topol
Nature Genetics|September 29, 2006
The genetics of healthJoseph H Nadeau, Eric J Topol
Nature Genetics|March 30, 2007
The resequencing imperativeEric J Topol, Kelly A Frazer
Pageof 61